| [1] |
Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.
Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study
[J]. Journal of International Oncology, 2024, 51(6): 326-331.
|
| [2] |
Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.
Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer
[J]. Journal of International Oncology, 2024, 51(6): 332-337.
|
| [3] |
Zhang Baihong, Yue Hongyun.
Advances in anti-tumor drugs with new mechanisms of action
[J]. Journal of International Oncology, 2024, 51(6): 354-358.
|
| [4] |
Xu Fenglin, Wu Gang.
Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma
[J]. Journal of International Oncology, 2024, 51(6): 359-363.
|
| [5] |
Wang Ying, Liu Nan, Guo Bing.
Advances of antibody-drug conjugate in the therapy of metastatic breast cancer
[J]. Journal of International Oncology, 2024, 51(6): 364-369.
|
| [6] |
Gao Fan, Wang Ping, Du Chao, Chu Yanliu.
Research progress on intestinal flora and non-surgical treatment of the colorectal cancer
[J]. Journal of International Oncology, 2024, 51(6): 376-381.
|
| [7] |
Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.
Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy
[J]. Journal of International Oncology, 2024, 51(5): 257-266.
|
| [8] |
Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.
Progress of ferroptosis-related mechanisms in osteosarcoma
[J]. Journal of International Oncology, 2024, 51(5): 308-311.
|
| [9] |
Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.
Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma
[J]. Journal of International Oncology, 2024, 51(4): 210-216.
|
| [10] |
Sa Qiang, Xu Hangcheng, Wang Jiayu.
Advances in immunotherapy for breast cancer
[J]. Journal of International Oncology, 2024, 51(4): 227-234.
|
| [11] |
Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.
Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer
[J]. Journal of International Oncology, 2024, 51(4): 235-238.
|
| [12] |
Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.
Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes
[J]. Journal of International Oncology, 2024, 51(3): 143-150.
|
| [13] |
Qian Xiaotao, Shi Ziyi, Hu Ge.
A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma
[J]. Journal of International Oncology, 2024, 51(3): 151-156.
|
| [14] |
Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.
Progress of radiotherapy in oligometastatic non-small cell lung cancer
[J]. Journal of International Oncology, 2024, 51(3): 170-174.
|
| [15] |
Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.
Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer
[J]. Journal of International Oncology, 2024, 51(3): 175-180.
|
